However, the most recent study argued against NPM1 and FLT3ITD mutations being the sole determinants in AML prognosis, and another mutation, DNMT3A, must also be taken into consideration in the decision-making process of the treatment of NPM1-mutated AML [18]. Here, DNMT3A is linked to acute myeloid leukemia.